Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
Semaglutide is the active ingredient in three Novo Nordisk drugs that are being used for weight loss purposes:
- Ozempic, which was approved in 2017 by the FDA as a Type 2 diabetes treatment, such that Ozempic is being used "off-label" for weight loss;
- Rybelsus, approved in 2019 as Type 2 diabetes treatment, is also being used "off-label" for weight loss; and,
- Wegovy, which was approved in 2021 by the FDA as a treatment for adult obesity and "indicated" for weight loss (and, therefore, not "off-label").
In recent years we have seen an increasing number of adverse event reports for these Novo Nordisk semaglutide weight loss drugs that involve severe stomach conditions, including:
- Gastric Stasis
- Stomach Paralysis
For a general medical definition of these semaglutide-related stomach conditions, we turn to a National Library Medicine webpage titled "Gastric Stasis":
Gastroparesis (gastric stasis) is derived from Greek words gastro/gaster or stomach, and paresis or partial paralysis. It is a clinical condition resulting from delayed gastric emptying in the absence of mechanical obstruction and is associated with upper gastrointestinal symptoms. Most common symptoms include nausea, vomiting, early satiety, postprandial fullness, upper abdominal pain, bloating, and weight loss. These symptoms can be severely disabling and can adversely impact the quality of life in patients suffering from this disorder.
Strictly Confidential, No Obligation.
Given this explanation and description of these severe stomach conditions that have been linked to Ozempic, Rybelsus, and Wegovy, people experiencing gastroparesis or gastric stasis often go to the emergency department/emergency room (ER) of their local hospital, sometimes several different times, before finally being admitted to the hospital.
While an ER doctor may determine that a person using the semaglutide weight loss drug has developed severe stomach conditions and then orders hospital admission, the actual medical diagnosis of gastroparesis or gastric stasis is usually made by a gastroenterologist, also called a GI doctor.
Going back to the increasing number of adverse event reports for Ozempic, Rybelsus, and Wegovy that involve severe stomach conditions, drug injury lawsuits will likely filed against Novo Nordisk. These lawsuits would be based on the failure of Novo Nordisk to include an adequate warning in the drug labels for these semaglutide weight loss drugs about an increased risk of gastroparesis, gastric stasis, or stomach paralysis.
We are currently investigating Ozempic, Rybelsus, and Wegovy drug injury lawsuits for people diagnosed with gastroparesis, gastric stasis, or stomach paralysis, and hospitalized for one of those possible semaglutide-related stomach conditions.
If we can assist you or someone you know, you can contact me by email ([email protected]) or phone (800-426-9535).
Of course, we will continue to monitor the medical and regulatory realms for significant developments regarding severe stomach conditions involving the Novo Nordisk semaglutide weight loss drugs Ozempic, Rybelsus, and Wegovy.